Trials / Not Yet Recruiting
Not Yet RecruitingNCT06845241
Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
A Multi-center, Non-randomized, and Open-label Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
- Status
- Not Yet Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 68 (estimated)
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, non-randomized and open-label phase I/IIa clinical study to evaluate the safety, tolerability, and efficacy of ICP-490 in patients with relapsed or refractory non-hodgkin lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ICP-490 | Specified dose on specified days |
Timeline
- Start date
- 2025-02-01
- Primary completion
- 2028-07-01
- Completion
- 2028-12-01
- First posted
- 2025-02-25
- Last updated
- 2025-02-25
Locations
6 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06845241. Inclusion in this directory is not an endorsement.